Authored By: Sarah
11 Jul 2024

 Cushing Syndrome Market Size to grow by USD 616.66 million between 2024-2028

According to a research report “ Cushing Syndrome Market” by Type (Glucocorticoid receptor antagonists, Pituitary directed drugs, Steroidogenesis inhibitors) Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 616.66 million, at a CAGR of  14.7% during the forecast period. In the context of healthcare expenditure, the aging population represents a significant financial challenge for both developed and emerging economies. The endocrine system, which comprises hormone-producing tissues and organs, plays a crucial role in regulating various body functions. With aging, target tissues may exhibit reduced sensitivity to their controlling hormones, leading to potential hormonal imbalances. Furthermore, alterations in the quantity of hormones produced can further exacerbate these imbalances. Cushing Syndrome, a condition characterized by excessive production or intake of cortisol, is an example of such a hormonal disorder. This condition can lead to increased healthcare costs due to its associated complications, including obesity, diabetes, hypertension, and osteoporosis. As the global population ages, the prevalence of Cushing Syndrome and other hormonal disorders is expected to rise, necessitating increased investments in research and development of effective diagnostic and therapeutic interventions.

Browse market data tables, figures, and in-depth TOC on “Cushing Syndrome Market” by Type (Glucocorticoid receptor antagonists, Pituitary directed drugs, Steroidogenesis inhibitors) Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the Glucocorticoid receptor antagonists segment is projected to dominate the market size in 2024

In the healthcare industry, hospital pharmacies represent a significant segment for procuring and supplying pharmaceuticals directly to hospitals for the treatment of both outpatients and inpatients. These pharmacies stock a wide range of therapeutic and critical care drugs, applicable to various medical disciplines such as cardiology, neurology, urology, and infectious diseases. The primary objective of hospital pharmacies is to ensure the acquisition, storage, and distribution of medications within healthcare facilities. With an increasing demand for compounded drugs, hospital pharmacies have become the preferred distribution channel for these customized treatments. This sector is expected to maintain its market dominance throughout the forecast period.

By Distribution Channel, Hospital pharmacy  segment is expected to hold the largest market size for the year 2024

Mifepristone, a US Food and Drug Administration (FDA)-approved medication, serves as a glucocorticoid receptor antagonist in the treatment of Cushing syndrome. This drug is particularly effective in managing hyperglycemia in patients diagnosed with endogenous Cushing syndrome, who also exhibit diabetes mellitus or glucose intolerance. For patients who are ineligible for surgical intervention or have not responded positively to prior surgeries, Mifepristone represents a crucial alternative treatment. Glucocorticoid antagonists, such as Mifepristone, are rapidly effective in controlling hypercortisolism, making them indispensable in the management of Cushing syndrome, especially for those with severe disease or accompanying conditions necessitating swift cortisol reduction.

North America is forecasted to hold the largest market size by region in 2024

The North American Cushing Syndrome market is projected to expand at a consistent rate over the forecast period, driven by the increasing prevalence of this condition in the region. The US dominates the market due to the availability of approved treatments such as Isturisa (osilodrostat), Korlym (mifepristone), and Recorlev (levoketoconazole). Canada and Mexico are experiencing a rise in Cushing syndrome cases due to the growing incidence of hormonal disorders linked to unhealthy lifestyles. This trend positions North America as a significant contributor to the global Cushing Syndrome market.

The Cushing Syndrome Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Corcept Therapeutics Inc.
  • Perrigo Co. Plc
  • Recordati S.p.A
  • Xeris Biopharma Holdings Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Cushing's syndrome, a hormonal disorder caused by excessive production of cortisol, is a condition that affects approximately 15-20 people per million per year. The condition is more prevalent in the geriatric population and can be caused by various factors, including tumors in the pituitary gland or adrenal glands, chemotherapy, radiation therapy, or prolonged use of corticosteroid medication. Recent drug approvals for Cushing's syndrome include pasireotide, a somatostatin analog indicated for the treatment of Cushing's disease in adults, and mifepristone, a glucocorticoid receptor antagonist used off-label for the treatment of Cushing's syndrome. People with Cushing's syndrome may experience weight gain, round red face, acne, thinning skin, purple stretch marks, high blood pressure, abdominal obesity, weak muscles, and weak bones. Type 2 diabetes is also common in individuals with Cushing's syndrome. The condition can also lead to autoimmune diseases and inflammation. Treatment options for Cushing's syndrome include surgery to remove the tumor, radiation therapy, and medication to reduce cortisol production. Prednisone, a corticosteroid medication, can worsen symptoms in individuals with Cushing's syndrome due to its own cortisol-like effects. Therefore, it is important for individuals with Cushing's syndrome to avoid prolonged use of corticosteroid medication and seek appropriate treatment to manage their condition and prevent complications such as delicate skin, weak bones, and adipose tissue deposits.

Market Research Overview

Cushing Syndrome, a condition characterized by cortisol overproduction leading to hormonal imbalance, presents significant challenges for drug developers in the Phase IV stage. With a limited patient pool, safety profile and therapeutic efficacy are paramount. Clinical trials face hurdles due to the complex nature of the disease, which can be caused by Adrenal Gland Disorders or Pituitary Gland Disorders, and its association with Rare Diseases and Medical Conditions such as Type 2 diabetes, geriatric population, and autoimmune diseases. The market for Cushing Syndrome treatments is challenging due to high labor costs, raw material suppliers, and healthcare expenditure. Diagnosis of the disease requires advanced screening, and patient outcomes heavily depend on adherence rates and timely intervention. Market opportunities exist in emerging economies, where the incidence of lifestyle diseases and endocrine disorders is on the rise. Therapeutic options include surgical interventions, medications like Prednisone, and treatments for associated conditions such as high blood pressure, acne, and weight gain. Cushing Syndrome presents as a round red face, abdominal obesity, reddish stretch marks, weak muscles, and thin, purple stretch marks. Cortisol, the primary hormone involved, can lead to weak bones, hypertension, and inflammation. Drug approvals are crucial to improving patient outcomes and reducing mortality. Chemotherapy, radiation, and surgery are also used in the treatment of Cushing's Syndrome. Adherence rates and patient epidemiology analysis are essential to understanding the impact of these interventions on patient outcomes. The complexities of Cushing Syndrome require a multifaceted approach to drug development and treatment.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio
Document